According to DelveInsight, Generalized Pustular Psoriasis (GPP) market in 7MM is expected to change in the study period 2017-2030. A modest increase in the Generalized Pustular Psoriasis market size of currently prescribed therapies has been witnessed from 2017 until the launch of emerging therapies in respective countries. The market share is expected to decline post that for current therapies, across the 7MM, owing to the increasing demand for targeted therapies to treat GPP. Among the current treatment regimens, biologics occupy the highest number of prescriptions in the treatment market of GPP. Moreover, combination therapies remain the mainstay in the treatment of GPP, irrespective of the severity of the disease.
Like this book? You can publish your book online for free in a few